PIGA-Congenital Disorder of Glycosylation

Sponsored diagnostic testing programs for PIGA-Congenital Disorder of Glycosylation

PIGA-CDG is a GPI-anchor biosynthesis defect characterized by developmental delay, seizures, hypotonia, dysmorphic features, and sometimes elevated alkaline phosphatase or other organ involvement. Severity ranges from severe epileptic encephalopathy to milder presentations. Genetic testing confirms the diagnosis and informs supportive care and counseling.

1 program found for PIGA-Congenital Disorder of Glycosylation

Programs

1 program
Invitae Unlock™

Invitae Epilepsy Panel

This program provides access to genetic testing for pediatric patients under 18 who present with an unprovoked seizure. The panel evaluates key epilepsy-associated genes to support diagnostic confirmation, inform prognosis, and guide clinical management. Testing is available to eligible patients when ordered by a licensed healthcare provider.

Neurology